AU2009332883B2 - Oncolytic adenoviral vectors and methods and uses related thereto - Google Patents

Oncolytic adenoviral vectors and methods and uses related thereto Download PDF

Info

Publication number
AU2009332883B2
AU2009332883B2 AU2009332883A AU2009332883A AU2009332883B2 AU 2009332883 B2 AU2009332883 B2 AU 2009332883B2 AU 2009332883 A AU2009332883 A AU 2009332883A AU 2009332883 A AU2009332883 A AU 2009332883A AU 2009332883 B2 AU2009332883 B2 AU 2009332883B2
Authority
AU
Australia
Prior art keywords
cancer
cells
cell
subject
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009332883A
Other languages
English (en)
Other versions
AU2009332883A1 (en
Inventor
Vincenzo Cerullo
Akseli Hemminki
Anna Kanerva
Sari Pesonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncos Therapeutics Oy
Original Assignee
Oncos Therapeutics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20080671A external-priority patent/FI20080671A0/fi
Application filed by Oncos Therapeutics Oy filed Critical Oncos Therapeutics Oy
Publication of AU2009332883A1 publication Critical patent/AU2009332883A1/en
Application granted granted Critical
Publication of AU2009332883B2 publication Critical patent/AU2009332883B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009332883A 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto Ceased AU2009332883B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
FI20080671 2008-12-22
FI20080671A FI20080671A0 (fi) 2008-12-22 2008-12-22 Onkolyyttiset virukset
FI20095466A FI121508B (fi) 2008-12-22 2009-04-27 Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI20095466 2009-04-27
US58597109A 2009-09-29 2009-09-29
US12/585,971 2009-09-29
PCT/FI2009/051025 WO2010072900A1 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Publications (2)

Publication Number Publication Date
AU2009332883A1 AU2009332883A1 (en) 2011-07-07
AU2009332883B2 true AU2009332883B2 (en) 2015-05-21

Family

ID=44502296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009332883A Ceased AU2009332883B2 (en) 2008-12-22 2009-12-21 Oncolytic adenoviral vectors and methods and uses related thereto

Country Status (20)

Country Link
EP (1) EP2379586B1 (enExample)
JP (2) JP2012513209A (enExample)
KR (1) KR101761094B1 (enExample)
CN (1) CN102264760B (enExample)
AU (1) AU2009332883B2 (enExample)
BR (1) BRPI0924123B8 (enExample)
CA (1) CA2748180C (enExample)
CY (1) CY1120039T1 (enExample)
DK (1) DK2379586T3 (enExample)
ES (1) ES2612889T3 (enExample)
HR (1) HRP20170165T1 (enExample)
HU (1) HUE031689T2 (enExample)
LT (1) LT2379586T (enExample)
PL (1) PL2379586T3 (enExample)
PT (1) PT2379586T (enExample)
RU (1) RU2520823C2 (enExample)
SG (1) SG173432A1 (enExample)
SI (1) SI2379586T1 (enExample)
WO (1) WO2010072900A1 (enExample)
ZA (1) ZA201104224B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011070440A2 (en) 2009-12-10 2011-06-16 Ottawa Hospital Research Institute Oncolytic rhabdovirus
BR112013006699A2 (pt) * 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
EP2619224A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
JP2016513115A (ja) 2013-02-21 2016-05-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド ワクチン組成物
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
DK3461491T3 (da) 2013-04-18 2025-02-03 Tilt Biotherapeutics Oy Forbedret adoptiv celleterapi
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
FI127460B (en) 2016-01-15 2018-06-29 Targovax Oy Combining adenovirus and chemotherapeutic agents for treating cancer
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
LT3293201T (lt) 2016-09-12 2021-03-25 Targovax Oy Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui
US20190275092A1 (en) * 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
AU2018206304A1 (en) * 2017-01-06 2019-07-04 Stabilitech Biopharma Ltd Virus
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
JP7260173B2 (ja) 2017-04-21 2023-04-18 ベイラー カレッジ オブ メディスン 腫瘍溶解性ウイルス療法および免疫療法
BR112019024656A2 (pt) 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
WO2019093435A1 (ja) * 2017-11-08 2019-05-16 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
EP3725323A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
EP3725888A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase
EP3725322A1 (en) 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing granzyme and perforin
KR102601875B1 (ko) * 2020-03-25 2023-11-14 (주)큐리진 면역 회피성 항종양 아데노바이러스
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
CN118853767A (zh) * 2024-08-22 2024-10-29 华中科技大学同济医学院附属同济医院 一种新型溶瘤腺病毒载体及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068772A1 (es) * 2005-12-12 2007-06-21 Proyecto De Biomedicina Cima, S.L. Nuevos adenovirus recombinantes de replicacion condicionada (crad)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454445T1 (de) * 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
AU5464000A (en) * 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US20020045264A1 (en) * 2000-03-14 2002-04-18 During Matthew J. Production of chimeric capsid vectors
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20070292396A1 (en) * 2006-03-02 2007-12-20 Juan Fueyo Combination therapy with oncolytic adenovirus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068772A1 (es) * 2005-12-12 2007-06-21 Proyecto De Biomedicina Cima, S.L. Nuevos adenovirus recombinantes de replicacion condicionada (crad)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUO, J. et al., Clinical Cancer Research, 2008, vol. 14, pages 2450-2457 *
RAKI, M., et al., Gene Therapy, 2007, vol. 14, pages 1380-1388 *

Also Published As

Publication number Publication date
ES2612889T3 (es) 2017-05-19
JP2016019530A (ja) 2016-02-04
CA2748180A1 (en) 2010-07-01
KR20110096579A (ko) 2011-08-30
BRPI0924123B1 (pt) 2020-10-20
LT2379586T (lt) 2017-03-10
CA2748180C (en) 2017-06-20
CY1120039T1 (el) 2018-12-12
RU2520823C2 (ru) 2014-06-27
CN102264760B (zh) 2017-03-22
DK2379586T3 (en) 2017-02-06
EP2379586A1 (en) 2011-10-26
HRP20170165T1 (hr) 2017-04-07
CN102264760A (zh) 2011-11-30
AU2009332883A1 (en) 2011-07-07
BRPI0924123B8 (pt) 2021-05-25
HUE031689T2 (en) 2017-07-28
KR101761094B1 (ko) 2017-08-04
JP6280084B2 (ja) 2018-02-14
SI2379586T1 (sl) 2017-02-28
SG173432A1 (en) 2011-09-29
ZA201104224B (en) 2012-09-26
EP2379586B1 (en) 2016-11-02
JP2012513209A (ja) 2012-06-14
WO2010072900A1 (en) 2010-07-01
RU2011130511A (ru) 2013-01-27
PT2379586T (pt) 2017-02-09
PL2379586T3 (pl) 2017-08-31

Similar Documents

Publication Publication Date Title
EP2379586B1 (en) Oncolytic adenoviral vectors and methods and uses related thereto
US9345787B2 (en) Adenoviral vectors and methods and uses related thereto
AU2011306846B2 (en) Oncolytic adenoviral vectors and methods and uses related thereto
AU2011306845B2 (en) Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies
US9410129B2 (en) Recombinant serotype 5 (Ad5) adenoviral vectors
JP6639412B2 (ja) アルブミン結合部分を含んでなるアデノウイルス
CA2750770A1 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
FI121508B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
FI124926B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä
HK1161279A (en) Oncolytic adenoviral vetctors and methods and uses related thereto
HK1161279B (en) Oncolytic adenoviral vetctors and methods and uses related thereto
FI124927B (fi) Adenovirusvektoreita ja niihin liittyviä menetelmiä ja käyttöjä

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired